Alumis.png
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
February 28, 2025 09:08 ET | Alumis Inc.
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
Alumis.png
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
February 27, 2025 16:15 ET | Alumis Inc.
Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases
Alumis.png
Alumis Strengthens Leadership Team with Key Appointments
January 28, 2025 08:00 ET | Alumis Inc.
Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
January 14, 2025 07:00 ET | Kymera Therapeutics, Inc.
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...
Alumis.png
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
December 19, 2024 08:00 ET | Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
Alumis.png
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
November 14, 2024 16:05 ET | Alumis Inc.
Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).
Alumis.png
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
November 13, 2024 16:05 ET | Alumis Inc.
Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.
Alumis.png
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
September 27, 2024 09:00 ET | Alumis Inc.
Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis
Alumis.png
Alumis to Participate in Upcoming September Investor Conferences
September 03, 2024 16:29 ET | Alumis Inc.
Alumis will be participating in several investor conferences in September
Alumis.png
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
August 13, 2024 16:05 ET | Alumis Inc.
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...